Shots:
Angle and AstraZeneca entered into a supply agreement to develop and validate a methodology using ANGLE’s existing Parsortix-based DNA damage response (DDR) assay to detect micronuclei in CTCs as DDR measure
Assay development will occur in Guildford, UK, by the ANGLE’s laboratory, and follows development and launch of two highly specific and sensitive DDR assays in 2023
The time period for the development phase is 6 mos. AstraZeneca will pay £150,000 ($186.53M) to Angle
Ref: Angle | Image: Angle
Related News:- ANGLE Signs a Contract with Eisai for Liquid Biopsy Diagnostic Solution
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
